Assembly Biosciences (ASMB) to Post Quarterly Earnings on Wednesday

Assembly Biosciences (NASDAQ:ASMB) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.70) per share and revenue of $8.5990 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.11. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%.The business had revenue of $8.21 million during the quarter, compared to analysts’ expectations of $9.27 million. On average, analysts expect Assembly Biosciences to post $2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Assembly Biosciences Stock Performance

ASMB stock opened at $25.11 on Monday. The company’s 50 day moving average price is $25.84 and its 200 day moving average price is $27.47. Assembly Biosciences has a fifty-two week low of $16.90 and a fifty-two week high of $39.71. The firm has a market capitalization of $399.00 million, a price-to-earnings ratio of -228.25 and a beta of 1.10.

Hedge Funds Weigh In On Assembly Biosciences

Several hedge funds have recently added to or reduced their stakes in ASMB. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $5,476,000. Geode Capital Management LLC grew its position in shares of Assembly Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after buying an additional 1,212 shares during the last quarter. Marshall Wace LLP grew its position in shares of Assembly Biosciences by 51.5% in the 4th quarter. Marshall Wace LLP now owns 129,075 shares of the biopharmaceutical company’s stock valued at $4,390,000 after buying an additional 43,860 shares during the last quarter. Millennium Management LLC grew its position in shares of Assembly Biosciences by 354.6% in the 4th quarter. Millennium Management LLC now owns 98,221 shares of the biopharmaceutical company’s stock valued at $3,340,000 after buying an additional 76,613 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Assembly Biosciences during the 3rd quarter worth $3,120,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ASMB shares. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research note on Monday, May 4th. Wall Street Zen downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Mizuho set a $45.00 price objective on shares of Assembly Biosciences and gave the company an “outperform” rating in a report on Monday, June 15th. Guggenheim reaffirmed a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.